Anxiolytic-like effects of mitragynine in the open-field and elevated plus-maze tests in rats

Ammar Imad Hazim · Surash Ramanathan · Suhanya Parthasarathy · Mustapha Muzaimi · Sharif Mahsufi Mansor

Abstract The effects of mitragynine on anxiety-related behaviours in the open-field and elevated plus-maze tests were evaluated. Male Sprague–Dawley rats were orally treated with mitragynine (10, 20 and 40 mg/kg) or diazepam (10 mg/kg) 60 min before behavioural testing. Mitragynine doses used in this study were selected on the basis of approximately human equivalent doses with reference to our previous literature reports. Acute administration of mitragynine (10, 20 and 40 mg/kg) or diazepam (10 mg/kg) increased central zone and open arms exploration in the open-field and elevated plus-maze tests respectively. These anxiolytic-like effects of mitragynine were effectively antagonized by intraperitoneal administration of naloxone (2 mg/kg), flumazenil (10 mg/kg), sulpiride (0.5 mg/kg) or SCH 23390 (0.02 mg/kg) 15 min before mitragynine treatments. These findings reveal that the acute administration of mitragynine produces anxiolytic-like effects and this could be possibly attributed to the interactions among opioidergic, GABAergic and dopaminergic systems in brain regions involved in anxiety.

Keywords Anxiolytic · Mitragynine · Open-field · Elevated plus-maze

Introduction

Anxiety disorders are the most prevalent forms of mental illnesses [26]. Various classes of medications are currently in use to treat these disorders, with benzodiazepines being the commonest [40]. However, their use is limited by undesired side effects such as sedation, myorelaxation and development of dependence [20]. The use of alternative medicine, mostly herbal remedies, to treat mental disorders has increased significantly over the past few years as these are taken to be effective with fewer side effects than conventional drugs [3]. *Mitragyna speciosa* (Rubiaceae) is an indigenous tree growing in Southeast Asian countries, particularly in Malaysia and Thailand. The leaves of this plant are known as ‘Ketum’ or “Kratom” by indigenous people of Malaysia and Thailand. The leaves have been traditionally used by locals for their opium- and coca-like effects in enhancing work tolerance under intense tropical heat [11]. In addition, the leaves were also used to relieve pain, reduce coughing, treat diarrhoea, and to mitigate morphine withdrawal symptoms [46]. Over 25 alkaloids have been isolated from the mature leaves of *Mitragyna speciosa* with mitragynine being the most dominant active alkaloid in this plant [4]. Earlier studies reported the role of supraspinal opioid receptors and both descending noradrenergic and serotonergic systems in the antinociceptive effect of mitragynine [24, 25]. In addition, mitragynine suppressed the electrically stimulated contraction of guinea-pig ileum and mouse vas deferens through the activation of μ-, κ- and δ-opioid receptors [46, 47]. Recently, mitragynine has also been shown to produce an antidepressant-like effect in forced swimming and tail suspension tests [8] and decrease novel environment stress in mice [14]. Similarly, mitragynine attenuated stress-related behaviours in morphine-withdrawn zebrafish tested in a novel tank diving test [18]. It is well known that administration of opioid
agonists induces anxiolytic-like effects in laboratory animals \cite{33, 48} through interactions among opioidergic, \(\gamma\)-amino-butyric acid (GABA)ergic and dopaminergic systems in the brain \cite{19, 39}. In view of these findings, mitragynine being a psychotropic drug could have a beneficial effect on the prevention and management of stress-induced disorders such as anxiety. Therefore, the present study was conducted to evaluate the effect of mitragynine on anxiety-related behaviours using open-field (OF) and elevated plus-maze (EPM) tests. The possible involvements of opioidergic, GABAergic and dopaminergic systems in the observed effects of mitragynine were also investigated.

**Results and discussion**

Effects of mitragynine on anxiety-like behaviours in the OF and EPM tests

As shown in Fig. 1a and b, acute oral administration of mitragynine (10, 20 and 40 mg/kg) or diazepam (10 mg/kg) induced a significant increase in the number of entries (CZE) (Fig. 1a) and the percentage time spent in the central zone (%CZT) (Fig. 1b) of the OF, when compared to the control group \(p < 0.05\). Neither mitragynine nor diazepam significantly changed the overall locomotor activity (total distance travelled) (Fig. 1c). In the EPM test, acute administrations of mitragynine (10, 20 and 40 mg/kg) as well as diazepam (10 mg/kg,) significantly increased \(p < 0.05\) the percentage of open arm entries (%OAE) and the time spent on open arms (%OAT) of the plus-maze, when compared to the control group (Fig. 2a, b). On the other hand, acute administration of mitragynine or diazepam did not significantly affect the total number of arm visits in the elevated plus-maze test (Fig. 2c). As shown in Figs. 1 and 2, rats treated with 40 mg/kg mitragynine demonstrated highly significant \(p < 0.01\) changes in central zone and open arm exploration in the OF and the EPM tests respectively, therefore, this dose was chosen for the subsequent antagonism studies.

The role of the opioidergic system in the anxiolytic-like effect of mitragynine in the EPM test

Administration of naloxone alone did not significantly change the plus-maze activity when compared to the control group (Fig. 3a, b). However, a significant decrease in open arm activities was observed when naloxone was injected 15 min before oral or intraperitoneal administrations of mitragynine and morphine, respectively \(p < 0.05\; \text{Fig. 3a, b}\). Open arm exploration was significantly decreased in rats pretreated with naloxone (2 mg/kg) when compared to rats treated with mitragynine or morphine alone (Fig. 3a, b). However, acute administration of morphine did not significantly affect the total number of arm visits in the EPM test (Fig. 3c).

The role of the GABAergic system in the anxiolytic-like effect of mitragynine in the EPM test

Acute oral administration of mitragynine (40 mg/kg) or diazepam (10 mg/kg) demonstrated a significant increase
in the %OAE and %OAT of the plus-maze when compared to the control group (p < 0.001; Fig. 4a, b). These effects were significantly antagonized when flumazenil was injected 15 min before the oral administrations of mitragynine and diazepam (Fig. 4a, b). Acute intraperitoneal administration of flumazenil alone did not produce significant changes in the plus-maze activities when compared to the control group (Fig. 4a–c).
The role of the dopaminergic system in the anxiolytic-like effect of mitragynine in the EPM test

As shown in Fig. 5a, b, acute oral administration of mitragynine (40 mg/kg) or apomorphine (0.5 mg/kg) demonstrated a significant increase in the %OAE and %OAT of the plus-maze when compared to the control group ($p < 0.05$; Fig. 5a, b). In addition, acute intraperitoneal administration of sulpiride or SCH 23390 alone did not produce significant changes in the plus-maze activities when compared to the control group (Fig. 5a–c). However, open arm exploration was significantly decreased when sulpiride or SCH 23390 were injected 15 min before the oral or intraperitoneal administrations of mitragynine and apomorphine, respectively ($p < 0.05$; Fig. 5a, b).

OF and EPM tests have been widely used to assess anxiety-related behaviour in rodents [15, 29]. The OF test is based upon conflict between the innate tendency of rodents to explore novel environments and aversion to open spaces. The CZE and %CZT have been well established as a measure of anxiety state in the OF test [34]. Our results demonstrated that acute oral administration of mitragynine (10, 20 and 40 mg/kg) produced anxiolytic-like effects in the OF test, as shown by the increase in central zone activities. Similar effects were also observed following the oral administration of diazepam (10 mg/kg). These anxiolytic-like effects were also reinforced by the behavioural findings from the EPM model, which relies upon conflict between exploration and aversion to elevated open places. It has been previously reported that anxiolytics such as diazepam increase open-arm exploration in the EPM test [32]. In this study, mitragynine at three different doses (10, 20 and 40 mg/kg) demonstrated anxiolytic-like effects, and a similar effect was observed in the rat group administered diazepam (10 mg/kg). This is the first reported anxiolytic-like effects of mitragynine in rats at doses equivalent to the human dose derived from the informal consumption of air ketum [31, 44]. Whilst mitragynine is a psychotropic drug and the principal alkaloid in ketum, this anxiolytic-like effect may have some basis in the informal use of ketum to mitigate opiate withdrawal symptoms, but this warrants further studies.

Antagonism of these activities using naloxone in this study appeared to mitigate the anxiolytic-like effect of mitragynine as well as that of morphine in the EPM test. These findings are consistent with previous studies reporting mitragynine activation of opioid receptors, with high affinity for both μ- and κ- followed by δ-opioid receptor subtypes [2, 42]. Together, these findings strongly
implicate the role of the opioidergic system in the anxiolytic-like effects of mitragynine. Several lines of evidence indicate the role of opioid receptors in the behavioral response to anxiety. Microinjections of morphine into the ventral hippocampus or the nucleus accumbens decreased aversion to the open arms of the plus-maze, suggesting a potential role of µ-opioid receptors in the anxiolytic-like effect of morphine [48]. Previous studies have also reported that activation of κ- and δ-opioid receptors produce anxiolytic-like behaviour in rodents [33, 41]. Privette and Terrian [33] reported anxiolytic-like effects in rats following intraperitoneal administrations of κ-opioid receptor agonists U-50,488 H and U-69,593. These effects were significantly antagonized after pretreatment with naloxone. Similarly, bilateral administration of enkephalin into rat dorsal hippocampus has also shown to induce an anxiolytic-like effect via the activation of δ-opioid receptors [41].

It has been previously reported that opioid control of anxiety is mediated by indirect interactions with GABAergic [39, 43] and dopaminergic pathways [19, 36] in brain regions involved in fear and anxiety such as the amygdala, hypothalamus, hippocampus and midbrain areas. A study by Sasaki and colleagues [39] evaluated the interaction between opioidergic and GABAergic systems. In this study, administration of morphine to wild-type mice has been shown to enhance the anxiolytic-like effects of muscimol, a selective GABA_A agonist, in EPM tests, by raising its binding in posterior thalamic, mediodorsal thalamic and amygdaloid areas. However, these effects were not observed in µ-opioid receptor knockout mice. These findings suggest the crucial role of µ-opioid receptors in modulating anxiolytic behaviour regulated by GABAergic neurotransmission. Results from the same study have also shown that the anxiolytic-like effects observed following morphine administration to wild-type mice were effectively antagonized by naloxone as well as bicucullin, GABA_A antagonist. These results further confirm the role of interactions between opioidergic and GABAergic systems in modulating anxiety behaviours [39]. In another study, the interaction between κ-opioid and GABAergic systems was examined using the Vogel conflict model in mice. The anticonflict effect of diazepam was significantly abolished by pretreatment with naloxone or nor-binaltorphimine, the selective κ-opioid receptor antagonist, suggesting the involvement of the κ-opioid system in the anxiolytic-like effects of diazepam [43]. Although the exact mechanism of interaction between opioidergic and GABAergic systems is unknown, the co-location of GABA and opiate receptors in the central nervous system, and the existence of possible cross-reactivity and common path-

---

**Fig. 5** The effect of sulpiride (SLP) and SCH 23390 (SCH) on anxiolytic-like behaviours induced by mitragynine (MG) and apomorphine (APO) in rats. The animals received a pre-test injection of saline (1 ml/kg), SLP (0.5 mg/kg) or SCH (0.02 mg/kg) 15 min before MG (40 mg/kg) or APO (0.5 mg/kg) treatments. Control (5 ml/kg), SLP and SCH groups received saline (1 ml/kg) 15 min before treatments. The anxiolytic-like behaviour indices include changes in %OAE (a), %OAT (b) and the total arm entries (c). Each bar represents mean ± SEM. ****p < 0.001 when compared to control group; *p < 0.05 and +++p < 0.001 when compared to MG group; #p < 0.01 and ###p < 0.001 when compared to APO group.
ways of intracellular transduction may play a key role in this interaction [27]. Earlier studies have also reported the indirect modulation of dopamine cells by opioid agonists and endogenous opioid peptides [5, 6]. Stimulation of µ-opioid receptors, located presynaptically on the descending GABAergic axon terminals and interneurons innervating dopamine cells, enhances dopamine release in the ventral tegmental area by removing tonic inhibitory regulation of GABAergic input [17, 19]. In view of the opioid agonistic effect of mitragynine and the key role of GABAergic and dopaminergic systems in modulating anxiety behaviours [23, 28], the possible involvement of GABAergic and dopaminergic systems in mitragynine anxiolytic-like effects were investigated in this study. Our results demonstrated that pretreatment with flumazenil significantly reversed the anxiolytic-like effects of mitragynine and diazepam in the EPM test. Similarly, pretreatment with sulpiride or SCH 23390 significantly abolished the anxiolytic-like effects of mitragynine and apomorphine. These findings suggest the involvement of GABAergic and dopaminergic systems in the anxiolytic-like effect of mitragynine. It can therefore be assumed that mitragynine may produce anxiolytic-like effects by indirect modulation of GABAergic and dopaminergic systems through the activation of opioid receptors in brain regions involved in anxiety such as amygdala, hypothalamus, hippocampus and midbrain areas.

Mitragynine, at the doses employed (10, 20 and 40 mg/kg) did not show any sedative effect as evidenced by the total distance travelled in the OF, or the number of total arm entries in the EPM test. Our previous studies have shown that similar doses of mitragynine did not produce any muscle relaxant effect in the rota-rod test [14] and proved the wide therapeutic index of mitragynine compared to the alkaloid extract of Mitragyna speciosa leaves [37]. An earlier study by Macko and colleagues [22] has shown that single oral administration of 806 mg/kg mitragynine failed to produce toxicity signs in rats. Similarly, sub-acute administration of 50 mg/kg/day mitragynine for 5 days a week for 6 weeks did not show any toxic signs in rats [22]. In addition, our recent toxicity study has also shown that oral administration of 1 and 10 mg/kg mitragynine for 28 days did not exhibit toxicity signs in rats. However, administration of 100 mg/kg mitragynine for the same period of time produced significant toxicity as demonstrated by histopathological changes in the liver, kidney and brain as well as biochemical and haematological changes [38]. The probability of mitragynine causing dependence in humans is not well documented. A recent study reported the informal use of ketum to manage opiate withdrawal symptoms and reduce addiction to other drugs. Ketum users described it as affordable, easily available and having no serious side effects despite prolonged use [44]. In support of these findings, the most recent in vitro study has shown a low tendency of mitragynine to develop dependence and tolerance compared to morphine [16]. Human neuroblastoma cells treated with mitragynine demonstrated significantly fewer changes in cyclic adenosine monophosphate cAMP level and µ-opioid receptor expression during cell differentiation compared to morphine-treated cells. In addition, cells treated with both mitragynine and morphine demonstrated significantly fewer changes in cAMP level and µ-opioid receptor expression compared to morphine treatment alone, suggesting a possible role of mitragynine in avoiding the development of dependence and tolerance after chronic administration of morphine [16]. In another study, administration of morphine (5 mg/kg) for 9 days produced significant increases in cAMP and cAMP response element binding (CREB) expression in the thalamus and cortex of mice brains due to the development of cAMP transmission tolerance. However, no significant changes in these protein expressions were observed in mice treated with mitragynine (15 and 25 mg/kg) and morphine (5 mg/kg) for the same period of time. These results further support the role of mitragynine in preventing the development of tolerance following chronic administration of morphine [7]. Taken together, these findings tend to suggest that mitragynine is relatively safe and devoid of unwanted side effects such as the development of dependence and tolerance.

Experiments

Animals

Male Sprague-Dawley rats (weighing 170–200 g) were obtained from the Animal Research and Service Centre (ARASC), Universiti Sains Malaysia (USM). Rats were housed in polypropylene cages (40 × 34 × 17 cm) in groups of six for at least 1 week prior to behavioural testing, with free access to the standard commercial food pellets (Gold Coin Feed Mills Sdn Bhd, Malaysia) and water ad libitum. Rats were housed in a temperature-controlled room at 24 ± 1 °C and maintained on a reversed 12-h light/dark cycle (with lights off at 07:00 h). Behavioural tests were performed during the dark phase of the light cycle (09:00 to 12:00 h). The experimental protocols for care and use of laboratory animals described in this study were guided and approved by the Animal Ethics Committee, USM [USM/2010/58 (200)].

Drugs

Mitragynine was purified from the crude alkaloid extract of Mitragyna speciosa leaves as we previously described [1].
Morphine sulphate was provided by Hospital Universiti Sains Malaysia (Kelantan, Malaysia). Diazepam (GABA<sub>A</sub> receptor agonist) was purchased from Lipomed, Switzerland. Flumazenil (GABA<sub>A</sub> receptor antagonist), apomorphine hydrochloride (dopamine D<sub>1</sub> and D<sub>2</sub> receptor agonist), SCH23390 (dopamine D<sub>1</sub> receptor antagonist, (R)-(+)7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride), sulpiride (dopamine D<sub>2</sub> receptor antagonist) and naloxone hydrochloride dehydrate (opioid receptor antagonist) were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). All drugs were dissolved in sterile saline (0.9 % NaCl) just before the experiment, except for mitragynine and diazepam which were dissolved in 20 % (v/v) Tween 20 (ChemPur, Germany).

Treatments

The selection of mitragynine doses used in this study was based on recently published data on the informal use of ketum drink in the Northern Peninsula of Malaysia. Ketum users were found to consume 0.3–5.7 mg/kg/day mitragynine in ketum drink to wean off the opioid withdrawal symptoms [31, 44]. This translates to an equivalent dose range of 1.85–35.15 mg/kg mitragynine in rats [35]. Therefore, in the present study we administered three different doses of mitragynine (10, 20 and 40 mg/kg) orally to rats to examine their effects on anxiety behaviours. Prior to the experiments, animals were transferred to the testing room and habituated for 1 h. After each testing session, the apparatus was thoroughly cleaned with 70 % ethanol to eliminate the residual odours and traces of the previously tested animal. Differences in the behavioural data observed after the administration of 20 % Tween 20 or saline to rats were compared and found not significant (data not shown), which justified our choice to include only the Tween 20 group as control for comparison.

**Experiment 1: effects of mitragynine on anxiety-like behaviours in the open-field (OF) and elevated plus-maze (EPM) tests**

Five experimental groups (n = 8, each) were orally treated with different doses of mitragynine (10, 20 and 40 mg/kg), diazepam (10 mg/kg) or Tween 20 (5 ml/kg) 60 min before the OF test [14]; Popic et al. [32]. Immediately following the OF test, the animal was transferred to the EPM.

**Experiment 2: the role of the opioidergic system in the anxiolytic-like effect of mitragynine in the EPM test**

In this experiment, 48 rats were randomly divided into six experimental groups (n = 8, each). They were orally treated with mitragynine (40 mg/kg) or Tween 20 (5 ml/kg) 60 min before the EPM test. Morphine (6 mg/kg) and naloxone (2 mg/kg) were intraperitoneally administered 30 min before the test [30, 50]. To evaluate the possible involvement of the opioidergic system in the anxiolytic-like effects of mitragynine, two experimental groups were intraperitoneally administered naloxone (2 mg/kg) 15 min before mitragynine and morphine treatments [33]. Rats treated with mitragynine, control, morphine and naloxone were intraperitoneally administered saline solution (1 ml/kg) 15 min before oral or intraperitoneal treatments.

**Experiment 3: the role of the GABAergic system in the anxiolytic-like effect of mitragynine in the EPM test**

Forty-eight rats were used in this experiment. Animals were randomly divided into six experimental groups (n = 8, each). They were orally treated with mitragynine (40 mg/kg), diazepam (10 mg/kg) or Tween 20 (5 ml/kg) 60 min before the EPM test. Flumazenil (10 mg/kg) was intraperitoneally administered 15 min before the test [12]. To evaluate the possible involvement of the GABAergic system in the anxiolytic-like effects of mitragynine, two experimental groups were intraperitoneally administered flumazenil (10 mg/kg) 15 min before mitragynine and diazepam treatments [43]. Rats treated with mitragynine, control, diazepam and flumazenil were intraperitoneally administered saline solution (1 ml/kg) 15 min before oral or intraperitoneal treatments.

**Experiment 4: the role of the dopaminergic system in the anxiolytic-like effect of mitragynine in the EPM test**

In this experiment, 72 rats were randomly divided into nine groups (n = 8, each). Animals were orally treated with mitragynine (40 mg/kg) or Tween 20 (5 ml/kg) 60 min before the EPM test. Apomorphine (0.5 mg/kg), sulpiride (0.5 mg/kg) and SCH 23390 (0.02 mg/kg) were intraperitoneally administered 15 min before the plus-maze test [9]. To evaluate the putative involvement of the dopaminergic system in the anxiolytic-like effects of mitragynine, four experimental groups were intraperitoneally administered sulpiride (0.5 mg/kg) and SCH 23390 (0.02 mg/kg) 15 min before mitragynine and apomorphine treatments [9, 49]. Rats treated with mitragynine, control, apomorphine, sulpiride and SCH 23390 were intraperitoneally administered saline solution (1 ml/kg) 15 min before oral or intraperitoneal treatments.

**Behavioural testing**

**OF test**

The OF apparatus (Panlab, Spain) consisted of a black-painted wood arena (45 × 45 cm) with 50-cm high walls.
The arena was virtually divided by software (ActiTrack, Panlab, Spain) into central and peripheral zones. Rats were individually placed at the centre of the arena and allowed to freely explore the apparatus for 5 min [29]. Activities in the central zone, including the number of entries (CZE) and the percentage of time spent in the central zone (%CZT) were automatically recorded by infrared beams and taken as a measure of anxiety [10]. The overall motor activity during the OF test was considered as the total distance travelled as previously described [13].

EPM test

The test was performed as described elsewhere [45]. The plus-maze (Columbus Instruments, Ohio, USA) consisted of two open (50 × 10 cm) and two closed (50 × 10 × 40 cm) arms, extending from a central platform (10 × 10 cm). The apparatus was made of stainless steel and elevated to a height of 50 cm above the floor. Rats were individually placed at the centre of the maze, facing an open arm and allowed to freely explore the maze for 5 min. The time spent on the open and closed arms and the number of entries made into each arm was recorded using a video camera (Sony, DCR-SX44E). Arm entries were defined as entry of all four paws into an arm. The percentage of time spent on open arms (%OAT) (100 × time on open arms/total time spent in all arms) and the percentage of open arm entries (%OAE) (100 × number of open arm entries/total entries into all arms) were used as a measure of anxiety [15]. The number of total arm entries was used as a measure of spontaneous locomotor activity [21].

Statistical analysis

Statistical analysis was performed with SigmaPlot 11.0 software, using one-way analysis of variance (ANOVA) followed by Duncan’s post hoc test for multiple comparisons. Data that did not pass normality or homogeneity of variance were analysed using a Kruskal–Wallis test and sons. Data that did not pass normality or homogeneity of variance were analysed using a Kruskal–Wallis test and followed by Duncan’s post hoc test for multiple comparisons. Results were expressed as mean ± standard error of mean (SEM). p values <0.05 were considered statistically significant.

Conclusions

In conclusion, acute oral dosages of mitragynine (10, 20 and 40 mg/kg) produced anxiolytic-like effects in the OF and EPM tests similar to diazepam at the doses tested. These effects could be mediated via interactions among opioidergic, GABAergic and dopaminergic systems in brain regions involved in anxiety. However, this finding warrants further investigation and the identification of the exact mechanisms and brain regions involved in the anxiolytic-like effect of mitragynine are worth pursuing.

Acknowledgments We thank Ms. Vemala Devi for her advice and help with the statistical analysis. This work was made possible by the support of a Ministry of Science, Technology and Innovation (MOSTI) Research Grant and USM Research University Grant.

References

1. Beng GT, Hamdan MR, Siddiqui MJ, Mordà MN, Mansor SM (2011) A simple and cost effective isolation and purification protocol of mitragynine from Mitragyna speciosa Korth (ketum) leaves. Mal J Anal Sci 15:54–60
2. Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH (2008) Self-treatment of opioid withdrawal using kratom (Mitragyna speciosa korth). Addiction 103:1048–1050
3. Carlini EA (2003) Plants and the central nervous system. Pharmacol Biochem Behav 75:501–512
4. Chitrakarn S, Sawangjaroen K, Prasethto S, Janchawee B, Kawpradub N (2008) Inhibitory effects of kratom leaf extract (Mitragyna speciosa Korth) on the rat gastrointestinal tract. J Ethnopharmacol 116:173–178
5. Dilts RP, Kalivas PW (1989) Autoradiographic localization of mu-opioid and neurotensin receptors within the mesolimbic dopamine system. Brain Res 488:311–327
6. Dilts RP, Kalivas PW (1990) Autoradiographic localization of delta opioid receptors within the mesocorticlimbic dopamine system using radioiodinated [2- D-penicillamine, 5- D-penicillamine] enkephalin (125I-DPDPDE). Synapse 6:121–132
7. Fakurazi S, Abdul Rahman S, Taufik Hidayat M, Ithnin H, Moklas MAA, Arulselvan P (2013) The combination of mitragynine and morphine prevents the development of morphine tolerance in mice. Molecules 18:666–681
8. Garcia AM, Martinez R, Brandão ML, Morato S (2005) Effects of apomorphine on rat behavior in the elevated plus-maze. Physiol Behav 85:440–407
9. Garcia AM, Martínez R, Brandão ML, Morato S (2005) Effects of apomorphine on rat behavior in the elevated plus-maze. Physiol Behav 85:440–447
10. Charoenphandhu N, Teerapornpuntakit J, Lapmanee S, Dorkkam (2011) A simple and cost effective isolation and purification protocol of mitragynine from Mitragyna speciosa Korth (ketum) leaves. Mal J Anal Sci 15:54–60
11. Grewal KS (1932) Observations on the pharmacology of mitragynine. J Pharmacol Exp Ther 46:251–271
12. Griebel G, Simiand J, Serradeil-Le Gal C, Waggon J, Pascual M, Scatton B, Maffrand JP, Soubrie P (2002) Anxiolytic- and anti-depressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99:6370–6375
13. Grundmann O, Nakajima J, Serradeil-Le Gal C, Waggon J, Pascual M, Scatton B, Maffrand JP, Soubrie P (2002) Anxiolytic- and anti-depressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99:6370–6375
14. Hazim AI, Mustapha M, Mansor SM (2011) The effects on motor behaviour and short-term memory tasks in mice following an acute administration of Mitragyna speciosa alkaloid extract and mitragynine. J Med Plants Res 5:5810–5817
15. Hellion-Ibarrola MC, Ibarrola DA, Montalbetti Y, Kennedy ML, Heinichen O, Campuzano M, Tortoriello J, Fernández S,
20. Langen B, Egerland U, Bernoster K, Dost R, Unverferth K, Rundel (2019). Regulation of mitragynine on cAMP formation and mRNA expression of mu-opioid receptors mediated by chronic morphine treatment in SK-N-SH neuroblastoma cell. J Ethnopharmacol 148:135–143

21. Liu J, Garza JC, Bronner J, Kim CS, Zhang W, Lu XY (2010). Acute administration of leptin produces anxiolytic-like effects: a comparison with fluoxetine. Psychopharmacol (Berl) 207:535–545

22. Macko E, Weisbach JA, Douglas B (1972). Some observations on the pharmacology of mitragynine. Arch Int Pharmacodyn Ther 198:145–161

23. Maruyama K, Shimoju R, Ohkubo R, Maruyama H, Kurosawa M (2006). Involvement of mu-opioid receptors mediated by chronic morphine treatment in the inhibition of electrically stimulated gastrointestinal motility in mice. Brain Res 1110:135–143

24. Matsumoto K, Mizowaki M, Suchittra T, Murakami Y, Takayama H, Sakai S, Aimi N, Watanabe H (1996). Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems. Eur J Pharmacol 317:75–81

25. Matsumoto K, Mizowaki M, Suchittra T, Takayama H, Sakai S, Aimi N, Watanabe H (1996). Antinociceptive action of mitragynine in mice: evidence for the involvement of supraspinal opioid receptors. Life Sci 59:1149–1155

26. Matsuoka M, Matsushita H, Tomizawa K, Matsu H (2012). Tactile skin stimulation increases dopamine release in the nucleus accumbens in rats. J Physiol Sci 62:259–266

27. Matsumi K, Mizowaki M, Suchittra T, Murakami Y, Takayama H, Sakai S, Aimi N, Watanabe H (1996). Antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems. Eur J Pharmacol 317:75–81

28. Nikolaus S, Antke C, Beu M, Müller HW (2010). Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders—results from in vivo imaging studies. Rev Neurosci 21:119–139

29. Okajima D, Kudo C, Kobu R, Maruyama H, Kurosawa S (2001). Characterization in rats of the anxiolytic potential of zol-2-on, a new agonist at the benzodiazepine binding site of the GABAα receptor. J Pharmacol Exp Ther 319:244–252

30. Privette TH, Terrian DM (1995). Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze. Psychopharmacol 118:444–450

31. Privette TH, Terrian DM (1995). Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze. Psychopharmacol 118:444–450

32. Privette TH, Terrian DM (1995). Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze. Psychopharmacol 118:444–450

33. Prut L, Belzung C (2003). The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463:3–33

34. Reagan-Shaw S, Nihal M, Ahmad N (2008). Dose translation from animal to human studies revisited. FASEB J 22:659–661

35. Rezayof A, Hosseini SS, Zarrindast MR (2009). Effects of mitragynine on rat behaviour in the elevated plus maze: the role of central amygdala dopamine receptors. Behav Brain Res 202:171–178

36. Rezayof A, Hosseini SS, Zarrindast MR (2009). Effects of mitragynine on rat behaviour in the elevated plus maze: the role of central amygdala dopamine receptors. Behav Brain Res 202:171–178

37. Sabetghadam A, Navaratnam V, Mansor SM (2013). Dose–response relationship, acute toxicity, and therapeutic index between the alkaloid extract of Mitragyna speciosa and its main active compound mitragynine in mice. Drug Dev Res 74:23–30

38. Sabetghadam A, Ramanathan S, Sasidharan S, Mansor SM (2013). Subchronic exposure to mitragynine, the principal alkaloid of Mitragyna speciosa, in rats. J Ethnopharmacol 146:815–823

39. Sasaki K, Fan LW, Tien LT, Ma T, Loh HH, Ho IK (2002). The interaction of morphine and gamma-amino butyric acid (GABA)ergic systems in anxiolytic behavior: using mu-opioid receptor knockout mice. Brain Res Bull 57:689–694

40. Shader RI, Greenblatt DJ (1993). Use of benzodiazepines in anxiety disorders. N Engl J Med 328:1398–1405

41. Solati J, Zarrindast M, Salar AA (2010). Dorsal hippocampal opioidergic system modulates anxiety-like behaviors in adult male Wistar rats. Psych Clin Neurosci 64:634–641

42. Tautuk Hidayat M, Apyrani E, Nabishah B, Moklas MAA, Shrida F, Farhan MA (2010). Determination of mitragynine bound opioid receptors. Adv Med Dent Sci 3:65–70

43. Tsuda M, Suzuki T, Misawa M, Nagase H (1996). Involvement of the opioid system in the anxiolytic effect of diazepam in mice. Eur J Pharmacol 307:7–14

44. Vicknasingam B, Narayanan S, Beng GT, Mansor SM (2010). The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. Int J Drug Policy 21:283–288

45. Walf AA, Frye CA (2007). The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2:322–328

46. Watanabe K, Yano S, Horie S, Yamamoto LT (1997). Inhibitory effect of mitragynine, an alkaloid with analgesic effect from Thai medicinal plant Mitragyna speciosa, on electrically stimulated contraction of isolated guinea-pig ileum through the opioid receptor. Life Sci 60:933–942

47. Yamamoto LT, Horie S, Takayama H, Aimi N, Sakai S, Yano S, Shan J, Pang PK, Ponglux D, Watanabe K (1999). Opioid receptor agonist characteristics of mitragynine pseudoinodoxyl in comparison with mitragynine derived from Thai medicinal plant Mitragyna speciosa, on electrically stimulated contraction of isolated guinea-pig ileum through the opioid receptor. Life Sci 60:933–942

48. Zarrindast MR, Babapoor-Farrokhran S, Babapoor-Farrokhran S, Rezayof A (2008). Involvement of opioidergic system of the ventral hippocampus, the nucleus accumbens or the central amygdala in anxiety-related behavior. Life Sci 82:1175–1181

49. Zarrindast MR, Esfahani DE, Oryan S, Nasehi M, Nami MT (2013). Effects of mitragynine receptor agonist and antagonists on cholestatic-induced anxiolytic-like behaviors in rats. Eur J Pharmacol 702:25–31

50. Zarrindast MR, Rostami P, Zarei M, Roobhaksh A (2005). Intracerebroventricular effects of histaminergic agents on morphine-induced anxiolysis in the elevated plus-maze in rats. Basic Clin Pharmacol Toxicol 97:276–281